

Anwar R Padhani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5186626/publications.pdf>

Version: 2024-02-01

290
papers

27,304
citations

5248

83
h-index

6630

156
g-index

295
all docs

295
docs citations

295
times ranked

20064
citing authors

#	ARTICLE	IF	CITATIONS
1	Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations. <i>Neoplasia</i> , 2009, 11, 102-125.	2.3	1,703
2	Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. <i>European Urology</i> , 2019, 76, 340-351.	0.9	1,270
3	Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). <i>Lancet, The</i> , 2005, 365, 1769-1778.	6.3	927
4	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186.	12.5	792
5	Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting. <i>European Urology</i> , 2011, 59, 477-494.	0.9	642
6	Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. <i>International Journal of Radiation Biology</i> , 2006, 82, 699-757.	1.0	561
7	Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. <i>European Urology</i> , 2019, 75, 570-578.	0.9	521
8	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	0.9	488
9	The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. <i>British Journal of Cancer</i> , 2005, 92, 1599-1610.	2.9	487
10	Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. <i>European Urology</i> , 2016, 69, 41-49.	0.9	454
11	Diffusion MRI for prediction of response of rectal cancer to chemoradiation. <i>Lancet, The</i> , 2002, 360, 307-308.	6.3	437
12	Dynamic contrast-enhanced MRI in clinical oncology: Current status and future directions. <i>Journal of Magnetic Resonance Imaging</i> , 2002, 16, 407-422.	1.9	415
13	Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging. <i>Journal of Clinical Oncology</i> , 2003, 21, 2831-2842.	0.8	328
14	Technology Insight: water diffusion MRI—a potential new biomarker of response to cancer therapy. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 220-233.	4.3	326
15	Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. <i>NMR in Biomedicine</i> , 2002, 15, 132-142.	1.6	323
16	Dynamic Contrast Enhanced MRI of Prostate Cancer: Correlation with Morphology and Tumour Stage, Histological Grade and PSA. <i>Clinical Radiology</i> , 2000, 55, 99-109.	0.5	320
17	Imaging oxygenation of human tumours. <i>European Radiology</i> , 2007, 17, 861-872.	2.3	304
18	Whole-Body Diffusion-weighted MR Imaging in Cancer: Current Status and Research Directions. <i>Radiology</i> , 2011, 261, 700-718.	3.6	293

#	ARTICLE	IF	CITATIONS
19	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2015, 26, 1589-1604.	0.6	279
20	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
21	Body diffusion kurtosis imaging: Basic principles, applications, and considerations for clinical practice. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1190-1202.	1.9	274
22	Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning. <i>Radiotherapy and Oncology</i> , 1997, 42, 1-15.	0.3	266
23	Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 44, 525-533.	0.4	262
24	Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. <i>NMR in Biomedicine</i> , 2002, 15, 154-163.	1.6	250
25	Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6580-6589.	3.2	250
26	Bone metastases. <i>Nature Reviews Disease Primers</i> , 2020, 6, 83.	18.1	246
27	The RECIST criteria: implications for diagnostic radiologists. <i>British Journal of Radiology</i> , 2001, 74, 983-986.	1.0	238
28	METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. <i>European Urology</i> , 2017, 71, 81-92.	0.9	230
29	Prediction of Clinicopathologic Response of Breast Cancer to Primary Chemotherapy at Contrast-enhanced MR Imaging: Initial Clinical Results. <i>Radiology</i> , 2006, 239, 361-374.	3.6	224
30	Dynamic Contrast-enhanced MRI Studies in Oncology with an Emphasis on Quantification, Validation and Human Studies. <i>Clinical Radiology</i> , 2001, 56, 607-620.	0.5	220
31	Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 649-656.	0.4	219
32	Diffusion-weighted imaging (DWI) in musculoskeletal MRI: a critical review. <i>Skeletal Radiology</i> , 2011, 40, 665-681.	1.2	219
33	Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. <i>British Journal of Surgery</i> , 2002, 88, 1628-1636.	0.1	212
34	Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). <i>Radiology</i> , 2019, 291, 5-13.	3.6	209
35	Multiparametric Imaging of Tumor Response to Therapy. <i>Radiology</i> , 2010, 256, 348-364.	3.6	201
36	Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions. <i>European Urology</i> , 2019, 75, 385-396.	0.9	200

#	ARTICLE	IF	CITATIONS
37	Dynamic contrast enhanced MRI in prostate cancer. <i>European Journal of Radiology</i> , 2007, 63, 335-350.	1.2	196
38	Probing tumor microvasculature by measurement, analysis and display of contrast agent uptake kinetics. <i>Journal of Magnetic Resonance Imaging</i> , 1997, 7, 564-574.	1.9	191
39	Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations—A Report of a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 648-655.	0.9	190
40	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists'™ training. <i>European Radiology</i> , 2020, 30, 5404-5416.	2.3	185
41	Reproducibility of quantitative dynamic MRI of normal human tissues. <i>NMR in Biomedicine</i> , 2002, 15, 143-153.	1.6	183
42	BOLD MRI of human tumor oxygenation during carbogen breathing. <i>Journal of Magnetic Resonance Imaging</i> , 2001, 14, 156-163.	1.9	175
43	Diffusion-weighted MR Imaging of Female Pelvic Tumors: A Pictorial Review. <i>Radiographics</i> , 2009, 29, 759-774.	1.4	165
44	PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. <i>Radiology</i> , 2019, 292, 464-474.	3.6	162
45	Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3428-3439.	3.2	158
46	Whole-Body Diffusion-Weighted MRI: Tips, Tricks, and Pitfalls. <i>American Journal of Roentgenology</i> , 2012, 199, 252-262.	1.0	158
47	Dynamic magnetic resonance imaging of tumor perfusion. <i>IEEE Engineering in Medicine and Biology Magazine</i> , 2004, 23, 65-83.	1.1	155
48	Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. <i>European Radiology</i> , 2009, 19, 2728-2738.	2.3	151
49	Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging. <i>Journal of Clinical Oncology</i> , 2002, 20, 3826-3840.	0.8	150
50	Tumor response assessments with diffusion and perfusion MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 745-763.	1.9	150
51	CT Perfusion in Oncologic Imaging: A Useful Tool?. <i>American Journal of Roentgenology</i> , 2013, 200, 8-19.	1.0	146
52	Diffusion-weighted imaging outside the brain: Consensus statement from an ISMRM-sponsored workshop. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 521-540.	1.9	146
53	Effects of Androgen Deprivation on Prostatic Morphology and Vascular Permeability Evaluated with MR Imaging. <i>Radiology</i> , 2001, 218, 365-374.	3.6	143
54	Diffusion-weighted MRI: a new functional clinical technique for tumour imaging. <i>British Journal of Radiology</i> , 2006, 79, 633-635.	1.0	142

#	ARTICLE	IF	CITATIONS
55	Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. <i>European Radiology</i> , 2012, 22, 1451-1464.	2.3	138
56	Prostate cancer: ESMO Consensus Conference Guidelines 2012. <i>Annals of Oncology</i> , 2013, 24, 1141-1162.	0.6	137
57	Assessing the Relation Between Bone Marrow Signal Intensity and Apparent Diffusion Coefficient in Diffusion-Weighted MRI. <i>American Journal of Roentgenology</i> , 2013, 200, 163-170.	1.0	137
58	Lung Cancer Perfusion at Multi-Phase Detector Row CT: Reproducibility of Whole Tumor Quantitative Measurements. <i>Radiology</i> , 2006, 239, 547-553.	3.6	132
59	MRI for assessing antivasular cancer treatments. <i>British Journal of Radiology</i> , 2003, 76, S60-S80.	1.0	131
60	Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1309-1315.	0.4	128
61	Rectal Carcinoma: MRI with Histologic Correlation Before and After Chemoradiation Therapy. <i>American Journal of Roentgenology</i> , 2007, 188, 442-451.	1.0	123
62	Diffusion MR Imaging for Monitoring of Treatment Response. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2011, 19, 181-209.	0.6	123
63	¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography in the Prediction of Relapse in Patients With High-Risk, Clinical Stage I Nonseminomatous Germ Cell Tumors: Preliminary Report of MRC Trial TE22 The NCRITestis Tumour Clinical Study Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 3090-3095.	0.8	122
64	A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. <i>Annals of Oncology</i> , 1997, 8, 995-1001.	0.6	121
65	Assessment of antiangiogenic and antivasular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. <i>British Journal of Radiology</i> , 2003, 76, S87-S91.	1.0	121
66	Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 48-58.	1.9	119
67	In vivo monitoring of tumor angiogenesis with MR imaging. <i>Academic Radiology</i> , 2000, 7, 812-823.	1.3	117
68	Antivasular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. <i>Abdominal Imaging</i> , 2005, 30, 325-342.	2.0	116
69	High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. <i>European Urology</i> , 2019, 76, 574-581.	0.9	114
70	Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. <i>British Journal of Cancer</i> , 2006, 95, 801-810.	2.9	113
71	FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. <i>British Journal of Cancer</i> , 2000, 83, 287-293.	2.9	111
72	Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1963-1996.	0.8	107

#	ARTICLE	IF	CITATIONS
73	National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection – recommendations from a UK consensus meeting. <i>BJU International</i> , 2018, 122, 13-25.	1.3	106
74	Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. <i>Magnetic Resonance Imaging</i> , 2000, 18, 765-776.	1.0	104
75	Assessment of Treatment Response by Total Tumor Volume and Global Apparent Diffusion Coefficient Using Diffusion-Weighted MRI in Patients with Metastatic Bone Disease: A Feasibility Study. <i>PLoS ONE</i> , 2014, 9, e91779.	1.1	104
76	The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2013, 17, vii-xix, 1-281.	1.3	102
77	Reading Protocol for Dynamic Contrast-enhanced MR Images of the Breast: Sensitivity and Specificity Analysis. <i>Radiology</i> , 2005, 236, 779-788.	3.6	99
78	Therapy monitoring of skeletal metastases with whole-body diffusion MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 39, 1049-1078.	1.9	99
79	Functional MRI for anticancer therapy assessment. <i>European Journal of Cancer</i> , 2002, 38, 2116-2127.	1.3	96
80	Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. <i>Targeted Oncology</i> , 2010, 5, 39-52.	1.7	95
81	Use of Dynamic Contrast-enhanced MR Imaging to Predict Survival in Patients with Primary Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Radiology</i> , 2011, 260, 68-78.	3.6	95
82	Functional imaging of colorectal cancer angiogenesis. <i>Lancet Oncology</i> , The, 2007, 8, 245-255.	5.1	92
83	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	5.1	90
84	Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography. <i>JAMA Oncology</i> , 2021, 7, 395.	3.4	87
85	Magnetic Resonance Imaging Workbench: Analysis and Visualization of Dynamic Contrast-enhanced MR Imaging Data. <i>Radiographics</i> , 2006, 26, 621-632.	1.4	82
86	Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study.. <i>British Journal of Radiology</i> , 1999, 72, 590-597.	1.0	81
87	Bayesian Methods for Pharmacokinetic Models in Dynamic Contrast-Enhanced Magnetic Resonance Imaging. <i>IEEE Transactions on Medical Imaging</i> , 2006, 25, 1627-1636.	5.4	80
88	Symptomatic Brachial Plexopathy following Treatment for Breast Cancer: Utility of MR Imaging with Surface-Coil Techniques. <i>Radiology</i> , 2000, 214, 837-842.	3.6	79
89	Prostate MRI: Who, when, and how? Report from a UK consensus meeting. <i>Clinical Radiology</i> , 2013, 68, 1016-1023.	0.5	79
90	Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 417-424.	0.4	78

#	ARTICLE	IF	CITATIONS
91	The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway. <i>Lung Cancer</i> , 2003, 42, 283-290.	0.9	77
92	PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review. <i>American Journal of Roentgenology</i> , 2021, 216, 3-19.	1.0	76
93	Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review. <i>European Urology Oncology</i> , 2020, 3, 145-167.	2.6	75
94	Tumor Antivasular Effects of Radiotherapy Combined with Combretastatin A4 Phosphate in Human Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1375-1380.	0.4	73
95	Vascular characterisation of triple negative breast carcinomas using dynamic MRI. <i>European Radiology</i> , 2011, 21, 1364-1373.	2.3	73
96	Quantitative Assessment of Lung Cancer Perfusion Using MDCT: Does Measurement Reproducibility Improve with Greater Tumor Volume Coverage?. <i>American Journal of Roentgenology</i> , 2006, 187, 1079-1084.	1.0	72
97	Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus-based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy. <i>European Urology Oncology</i> , 2021, 4, 868-876.	2.6	72
98	Pulmonary sarcoidosis mimicking cryptogenic fibrosing alveolitis on CT. <i>Clinical Radiology</i> , 1996, 51, 807-810.	0.5	71
99	Novel Oncologic Drugs: What They Do and How They Affect Images. <i>Radiographics</i> , 2011, 31, 2059-2091.	1.4	71
100	Imaging tumor angiogenesis: functional assessment using MDCT or MRI?. <i>Abdominal Imaging</i> , 2006, 31, 194-199.	2.0	70
101	UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. <i>British Journal of Radiology</i> , 2018, 91, 20170577.	1.0	70
102	Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 1415-1425.	3.2	69
103	Magnetic resonance imaging of prostate cancer: Comparison of image quality using endorectal and pelvic phased array coils. <i>Clinical Radiology</i> , 1998, 53, 673-681.	0.5	68
104	Applications of sliding window reconstruction with cartesian sampling for dynamic contrast enhanced MRI. <i>NMR in Biomedicine</i> , 2002, 15, 174-183.	1.6	68
105	A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas. <i>Clinical Cancer Research</i> , 2009, 15, 4484-4492.	3.2	68
106	Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2012, 23, 231-237.	0.6	68
107	How clinical imaging can assess cancer biology. <i>Insights Into Imaging</i> , 2019, 10, 28.	1.6	68
108	Imaging Tumour Angiogenesis. <i>Cancer Imaging</i> , 2005, 5, 131-138.	1.2	65

#	ARTICLE	IF	CITATIONS
109	Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis. <i>British Journal of Surgery</i> , 2006, 93, 992-1000.	0.1	65
110	Study of tumor blood perfusion and its variation due to vascular normalization by anti-angiogenic therapy based on 3D angiogenic microvasculature. <i>Journal of Biomechanics</i> , 2009, 42, 712-721.	0.9	64
111	Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 164-182.	3.3	64
112	Perfusion MR Imaging of Extracranial Tumor Angiogenesis. <i>Topics in Magnetic Resonance Imaging</i> , 2004, 15, 41-57.	0.7	63
113	Bony metastases: assessing response to therapy with whole-body diffusion MRI. <i>Cancer Imaging</i> , 2011, 11, S129-S154.	1.2	63
114	Magnetic Resonance Imaging Assessment of Squamous Cell Carcinoma of the Anal Canal Before and After Chemoradiation: Can MRI Predict for Eventual Clinical Outcome?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 715-721.	0.4	62
115	Rationale for Modernising Imaging in Advanced Prostate Cancer. <i>European Urology Focus</i> , 2017, 3, 223-239.	1.6	62
116	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition. <i>European Urology</i> , 2020, 77, 457-468.	0.9	62
117	Challenges for imaging angiogenesis. <i>British Journal of Radiology</i> , 2001, 74, 886-890.	1.0	60
118	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation. <i>European Urology</i> , 2020, 77, 469-480.	0.9	59
119	Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?. <i>Annals of Oncology</i> , 2015, 26, 1048-1057.	0.6	58
120	A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 596-611.	2.0	58
121	Angiogenesis imaging in the management of prostate cancer. <i>Nature Reviews Urology</i> , 2005, 2, 596-607.	1.4	57
122	Carbogen breathing increases prostate cancer oxygenation: a translational MRI study in murine xenografts and humans. <i>British Journal of Cancer</i> , 2009, 100, 644-648.	2.9	56
123	The Role of Functional Imaging in Colorectal Cancer. <i>American Journal of Roentgenology</i> , 2010, 195, 54-66.	1.0	56
124	Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. <i>Clinical and Translational Imaging</i> , 2016, 4, 439-447.	1.1	56
125	MRIW: parametric analysis software for contrast-enhanced dynamic MR imaging in cancer.. <i>Radiographics</i> , 1998, 18, 497-506.	1.4	55
126	Antivascular Effects of Neoadjuvant Androgen Deprivation for Prostate Cancer: An In Vivo Human Study Using Susceptibility and Relaxivity Dynamic MRI. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 721-727.	0.4	54

#	ARTICLE	IF	CITATIONS
127	Analysis of Magnetic Resonance Imagingâ€‘directed Biopsy Strategies for Changing the Paradigm of Prostate Cancer Diagnosis. <i>European Urology Oncology</i> , 2020, 3, 32-41.	2.6	53
128	Primary Human Breast Adenocarcinoma: Imaging and Histologic Correlates of Intrinsic Susceptibility-weighted MR Imaging before and during Chemotherapy. <i>Radiology</i> , 2010, 257, 643-652.	3.6	52
129	Advanced Imaging Techniques in Evaluation of Colorectal Cancer. <i>Radiographics</i> , 2018, 38, 740-765.	1.4	52
130	Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses. <i>Radiologia Medica</i> , 2019, 124, 218-233.	4.7	52
131	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 529-537.	3.7	51
132	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	0.9	51
133	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 523-532.	5.2	50
134	Use of first line bronchoalveolar lavage in the immunosuppressed oncology patient. <i>Bone Marrow Transplantation</i> , 2001, 27, 967-971.	1.3	49
135	Dynamic MRI for imaging tumor microvasculature: Comparison of susceptibility and relaxivity techniques in pelvic tumors. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 25, 796-805.	1.9	48
136	Robot-assisted Radical Prostatectomy: Multiparametric MR Imagingâ€‘directed Intraoperative Frozen-Section Analysis to Reduce the Rate of Positive Surgical Margins. <i>Radiology</i> , 2015, 274, 434-444.	3.6	48
137	Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 32, 155-164.	1.9	47
138	Diffusion Magnetic Resonance Imaging in Cancer Patient Management. <i>Seminars in Radiation Oncology</i> , 2011, 21, 119-140.	1.0	47
139	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. <i>Radiology</i> , 2019, 292, 273-286.	3.6	46
140	CT Features of Pulmonary Nocardiosis. <i>Journal of Computer Assisted Tomography</i> , 1995, 19, 726-732.	0.5	45
141	Imaging of Tumor Angiogenesis for Radiologistsâ€‘Part 1: Biological and Technical Basis. <i>Current Problems in Diagnostic Radiology</i> , 2015, 44, 407-424.	0.6	45
142	Introducing the Node Reporting and Data System 1.0 (Node-RADS): a concept for standardized assessment of lymph nodes in cancer. <i>European Radiology</i> , 2021, 31, 6116-6124.	2.3	44
143	Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease. <i>Prostate</i> , 2016, 76, 1024-1033.	1.2	43
144	Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation. <i>BJU International</i> , 2021, 127, 175-178.	1.3	43

#	ARTICLE	IF	CITATIONS
145	Assessing Early Therapeutic Response to Bevacizumab in Primary Breast Cancer Using Magnetic Resonance Imaging and Gene Expression Profiles. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 71-74.	0.9	42
146	The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. <i>British Journal of Cancer</i> , 2006, 95, 1683-1688.	2.9	41
147	Where are we with imaging oxygenation in human tumours?. <i>Cancer Imaging</i> , 2005, 5, 128-130.	1.2	40
148	Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease. <i>PLoS ONE</i> , 2016, 11, e0153840.	1.1	40
149	Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. <i>European Radiology</i> , 2008, 18, 1414-1421.	2.3	39
150	Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer. <i>BJU International</i> , 2011, 108, 1716-1722.	1.3	39
151	Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients?. <i>European Radiology</i> , 2013, 23, 3466-3476.	2.3	39
152	Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer?. <i>Diagnostic and Interventional Radiology</i> , 2015, 22, 75-89.	0.7	39
153	Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 3: Targeted Biopsy. <i>European Urology</i> , 2020, 77, 481-490.	0.9	36
154	Whole-body magnetic resonance imaging (WB-MRI) for cancer screening: recommendations for use. <i>Radiologia Medica</i> , 2021, 126, 1434-1450.	4.7	36
155	Quantitative Analysis of Dynamic Contrast-Enhanced MR Images Based on Bayesian P-Splines. <i>IEEE Transactions on Medical Imaging</i> , 2009, 28, 789-798.	5.4	35
156	Science to Practice: What Does MR Oxygenation Imaging Tell Us about Human Breast Cancer Hypoxia?. <i>Radiology</i> , 2010, 254, 1-3.	3.6	35
157	The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 77, 109-116.	1.3	35
158	ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging. <i>European Radiology</i> , 2021, 31, 9567-9578.	2.3	34
159	Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies. <i>Health Technology Assessment</i> , 2019, 23, 1-270.	1.3	34
160	Commentary. Are current tumour response criteria relevant for the 21st century?. <i>British Journal of Radiology</i> , 2000, 73, 1031-1033.	1.0	33
161	Inter- and intraobserver variability in the evaluation of dynamic breast cancer MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2006, 24, 1316-1325.	1.9	33
162	Initial observations on the effect of irradiation on the liver-specific uptake of Levovist. <i>European Journal of Radiology</i> , 2002, 41, 192-199.	1.2	32

#	ARTICLE	IF	CITATIONS
163	Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Blood Oxygenation Level-Dependent Magnetic Resonance Imaging for the Assessment of Changes in Tumor Biology With Treatment. Journal of the National Cancer Institute Monographs, 2011, 2011, 103-107.	0.9	32
164	Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 281-284.	0.8	32
165	Whole-Body Magnetic Resonance Imaging in Oncology. Magnetic Resonance Imaging Clinics of North America, 2018, 26, 495-507.	0.6	32
166	Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting. BJU International, 2021, 127, 304-306.	1.3	32
167	The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours. British Journal of Cancer, 2001, 85, 1624-1626.	2.9	31
168	Surgical restraint in the management of liver trauma. British Journal of Surgery, 2005, 78, 1071-1075.	0.1	31
169	Coupled modeling of blood perfusion in intravascular, interstitial spaces in tumor microvasculature. Journal of Biomechanics, 2008, 41, 996-1004.	0.9	31
170	Dynamic optical breast imaging: A novel technique to detect and characterize tumor vessels. European Journal of Radiology, 2009, 69, 43-49.	1.2	31
171	Dynamic contrast-enhanced MRI studies in human tumours.. British Journal of Radiology, 1999, 72, 427-431.	1.0	30
172	Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. British Journal of Cancer, 2005, 93, 979-985.	2.9	30
173	The Value of Immediate Cytologic Evaluation for Needle Aspiration Lung Biopsy. Investigative Radiology, 1997, 32, 453-458.	3.5	30
174	Evaluation of a Prospective Scoring System Designed for a Multicenter Breast MR Imaging Screening Study. Radiology, 2006, 239, 677-685.	3.6	29
175	A Bayesian hierarchical model for the analysis of a longitudinal dynamic contrast-enhanced MRI oncology study. Magnetic Resonance in Medicine, 2009, 61, 163-174.	1.9	29
176	Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: Are signal intensity-time curves adequate?. Breast Cancer Research and Treatment, 2014, 147, 335-343.	1.1	28
177	Therapy Monitoring with Functional and Molecular MR Imaging. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 261-288.	0.6	28
178	Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment. EBioMedicine, 2016, 10, 109-116.	2.7	27
179	Whole-body magnetic resonance imaging (WB-MRI) for cancer screening in asymptomatic subjects of the general population: review and recommendations. Cancer Imaging, 2020, 20, 34.	1.2	27
180	Focus on the Quality of Prostate Multiparametric Magnetic Resonance Imaging: Synopsis of the ESUR/ESUI Recommendations on Quality Assessment and Interpretation of Images and Radiologists' Training. European Urology, 2020, 78, 483-485.	0.9	27

#	ARTICLE	IF	CITATIONS
181	What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century. British Journal of Radiology, 2020, 93, 20200562.	1.0	26
182	Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. Radiology, 2021, 299, 494-507.	3.6	26
183	Apparent diffusion coefficient measurements as very early predictive markers of response to chemotherapy in hepatic metastasis: A preliminary investigation of reproducibility and diagnostic value. Journal of Magnetic Resonance Imaging, 2014, 40, 448-456.	1.9	25
184	T1-W DCE-MRI:T1-Weighted Dynamic Contrast-Enhanced MRI. , 0, , 341-364.		24
185	Integrating multiparametric prostate MRI into clinical practice. Cancer Imaging, 2011, 11, S27-S37.	1.2	24
186	Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer. European Urology Oncology, 2018, 1, 208-214.	2.6	24
187	Detecting Prostate Cancer with Deep Learning for MRI: A Small Step Forward. Radiology, 2019, 293, 618-619.	3.6	24
188	A Single-Arm, Multicenter Validation Study of Prostate Cancer Localization and Aggressiveness With a Quantitative Multiparametric Magnetic Resonance Imaging Approach. Investigative Radiology, 2019, 54, 437-447.	3.5	24
189	Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated?. World Journal of Urology, 2020, 38, 531-545.	1.2	24
190	Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone. Radiology, 2020, 297, 622-629.	3.6	24
191	Comparative efficacy of and sequence choice for two oral contrast agents used during MR imaging.. American Journal of Roentgenology, 1999, 173, 173-178.	1.0	23
192	Imaging breast cancer response during neoadjuvant systemic therapy. Expert Review of Anticancer Therapy, 2005, 5, 893-905.	1.1	23
193	Reply to Erik Rud and Eduard Baco's Letter to the Editor re: Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16-40. European Urology, 2016, 70, e137-e138.	0.9	22
194	<scp>Whole-body magnetic resonance imaging</scp> for prostate cancer assessment: Current status and future directions. Journal of Magnetic Resonance Imaging, 2022, 55, 653-680.	1.9	22
195	Magnetic Resonance Imaging Before Prostate Biopsy: Time to Talk. European Urology, 2016, 69, 1-3.	0.9	21
196	Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and) Tj ETQq0 0 0 1gBT /Overdock 10 Tf		
197	Diagnostic Accuracy and Observer Agreement of the MRI Prostate Imaging for Recurrence Reporting Assessment Score. Radiology, 2022, 304, 342-350.	3.6	21
198	Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma. British Journal of Cancer, 2002, 86, 336-341.	2.9	20

#	ARTICLE	IF	CITATIONS
199	Can the completeness of radiological cancer staging reports be improved using proforma reporting? A prospective multicentre non-blinded interventional study across 21 centres in the UK. <i>BMJ Open</i> , 2018, 8, e018499.	0.8	20
200	MRI in the detection and management of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 239-252.	1.1	19
201	Numerical simulation of blood flow and interstitial fluid pressure in solid tumor microcirculation based on tumor-induced angiogenesis. <i>Acta Mechanica Sinica/Lixue Xuebao</i> , 2007, 23, 477-483.	1.5	19
202	Rethinking prostate cancer screening: could MRI be an alternative screening test?. <i>Nature Reviews Urology</i> , 2020, 17, 526-539.	1.9	19
203	Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF). <i>European Journal of Cancer</i> , 1995, 31, 2209-2214.	1.3	18
204	Evaluation by magnetic resonance imaging of the inferior vena cava in patients with non-seminomatous germ cell tumours of the testis metastatic to the retroperitoneum. <i>BJU International</i> , 1997, 79, 942-951.	1.3	18
205	Magnetic resonance imaging of induration in the irradiated breast. <i>Radiotherapy and Oncology</i> , 2002, 64, 157-162.	0.3	18
206	Advanced imaging of colorectal cancer: From anatomy to molecular imaging. <i>Insights Into Imaging</i> , 2016, 7, 285-309.	1.6	18
207	Delivering Clinical impacts of the MRI diagnostic pathway in prostate cancer diagnosis. <i>Abdominal Radiology</i> , 2020, 45, 4012-4022.	1.0	18
208	Diagnostic Performance of a Magnetic Resonance Imaging-directed Targeted plus Regional Biopsy Approach in Prostate Cancer Diagnosis: A Systematic Review and Meta-analysis. <i>European Urology Open Science</i> , 2022, 40, 95-103.	0.2	18
209	Baseline Multiparametric MRI for Selection of Prostate Cancer Patients Suitable for Active Surveillance: Which Features Matter?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 155-163.e6.	0.9	17
210	A multifaceted approach to quality in the MRI-directed biopsy pathway for prostate cancer diagnosis. <i>European Radiology</i> , 2021, 31, 4386-4389.	2.3	17
211	Multiphase display of spiral CT data of the pulmonary hila in patients with lung cancer. <i>Clinical Imaging</i> , 1995, 19, 252-257.	0.8	16
212	Dynamic MRI of breast hardness following radiation treatment. <i>Journal of Magnetic Resonance Imaging</i> , 2003, 17, 427-434.	1.9	16
213	Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy. <i>Clinical Oncology</i> , 2005, 17, 167-171.	0.6	16
214	A test of performance of breast MRI interpretation in a multicentre screening study. <i>Magnetic Resonance Imaging</i> , 2006, 24, 917-929.	1.0	16
215	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2019, 30, e3.	0.6	16
216	Contrast Medium or No Contrast Medium for Prostate Cancer Diagnosis. That Is the Question. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 13-22.	1.9	16

#	ARTICLE	IF	CITATIONS
217	Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 714-730.	2.6	16
218	Imaging of Tumor Angiogenesis for Radiologistsâ€™ Part 2: Clinical Utility. <i>Current Problems in Diagnostic Radiology</i> , 2015, 44, 425-436.	0.6	15
219	Measuring the Quality of Diagnostic Prostate Magnetic Resonance Imaging: A Urologistâ€™s Perspective. <i>European Urology</i> , 2021, 79, 440-441.	0.9	15
220	PET imaging of tumour hypoxia. <i>Cancer Imaging</i> , 2006, 6, 1-1.	1.2	15
221	Diffusion tensor imaging of the anal canal at 3 tesla: Feasibility and reproducibility of anisotropy measures. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 820-826.	1.9	14
222	Optimal source distribution for focal boosts using high dose rate (HDR) brachytherapy alone in prostate cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 121-125.	0.3	14
223	A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). <i>Journal of Clinical Oncology</i> , 2006, 24, 3015-3015.	0.8	14
224	Mediastinal venous anomalies: potential pitfalls in cancer diagnosis.. <i>British Journal of Radiology</i> , 1998, 71, 792-798.	1.0	13
225	Arterial input functions in dynamic contrast-enhanced magnetic resonance imaging: which model performs best when assessing breast cancer response?. <i>British Journal of Radiology</i> , 2016, 89, 20150961.	1.0	13
226	Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: What We See and What We Miss. <i>European Urology</i> , 2019, 75, 721-722.	0.9	12
227	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. <i>European Journal of Cancer</i> , 2022, 160, 24-60.	1.3	12
228	Spiral CT: thoracic applications. <i>European Journal of Radiology</i> , 1998, 28, 2-17.	1.2	11
229	Statistical Analysis of Pharmacokinetic Models in Dynamic Contrast-Enhanced Magnetic Resonance Imaging. <i>Lecture Notes in Computer Science</i> , 2005, 8, 886-893.	1.0	11
230	Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels. <i>Cancer Imaging</i> , 2020, 20, 77.	1.2	11
231	Radiation induced liver injury detected by particulate reticuloendothelial contrast agent.. <i>British Journal of Radiology</i> , 1998, 71, 1089-1092.	1.0	10
232	Functional Magnetic Resonance Imaging of the Liver: Parametric Assessments Beyond Morphology. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2010, 18, 565-585.	0.6	10
233	Developments in MRI-targeted prostate biopsy. <i>Current Opinion in Urology</i> , 2020, 30, 1-8.	0.9	10
234	Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice. <i>Clinical Radiology</i> , 2020, 75, 950-956.	0.5	10

#	ARTICLE	IF	CITATIONS
235	Metastatic cardiac osteosarcoma–imaging features.. British Journal of Radiology, 1998, 71, 336-339.	1.0	9
236	Why do we need more accurate intraprostatic localization of cancer?. British Journal of Radiology, 2003, 76, 585-586.	1.0	9
237	Re: Variability of the Positive Predictive Value of PI-RADS for Prostate MRI Across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. European Urology, 2020, 78, 633-636.	0.9	9
238	Computed tomography in abdominal trauma: an audit of usage and image quality. British Journal of Radiology, 1992, 65, 397-402.	1.0	8
239	Computed tomography in blunt abdominal trauma: An analysis of clinical management and radiological findings. Clinical Radiology, 1992, 46, 304-310.	0.5	8
240	A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus. Annals of Oncology, 2002, 13, 1763-1770.	0.6	8
241	Diffusion-weighted MRI compared to FDG PET-CT in the staging and response assessment of Hodgkin lymphoma. British Journal of Haematology, 2012, 156, 557-557.	1.2	8
242	Metastasis Reporting and Data System for Prostate Cancer in Practice. Magnetic Resonance Imaging Clinics of North America, 2018, 26, 527-542.	0.6	8
243	Effects of Sex and Age on Fat Fraction, Diffusion-Weighted Image Signal Intensity and Apparent Diffusion Coefficient in the Bone Marrow of Asymptomatic Individuals: A Cross-Sectional Whole-Body MRI Study. Diagnostics, 2021, 11, 913.	1.3	8
244	Does vascular imaging with MRI predict response to neoadjuvant chemotherapy in primary breast cancer?. Journal of Clinical Oncology, 2004, 22, 582-582.	0.8	8
245	Chest radiography for general practitioners: Scope for change?. Clinical Radiology, 1992, 46, 51-54.	0.5	7
246	Problem in diagnostic imaging: Behind the left renal vein. , 1997, 10, 349-352.		7
247	Dynamic contrast-enhanced MR imaging. Cancer Imaging, 2000, 1, 52-63.	1.2	7
248	Platinum Opinion Counterinterview: The Evidence Base for the Benefit of Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis is Sound. European Urology, 2020, 78, 307-309.	0.9	7
249	Detection and Characterization of Musculoskeletal Cancer Using Whole-Body Magnetic Resonance Imaging. Seminars in Musculoskeletal Radiology, 2020, 24, 726-750.	0.4	7
250	Advances in imaging of colorectal cancer. Critical Reviews in Oncology/Hematology, 1999, 30, 189-199.	2.0	6
251	Problem in diagnostic imaging: Mediastinal venous anomalies. Clinical Anatomy, 2001, 14, 218-226.	1.5	6
252	Finding Minimal Extraprostatic Disease: Who Cares?. European Urology, 2016, 70, 246-247.	0.9	6

#	ARTICLE	IF	CITATIONS
253	Semi-Automated Segmentation of Bone Metastases from Whole-Body MRI: Reproducibility of Apparent Diffusion Coefficient Measurements. <i>Diagnostics</i> , 2021, 11, 499.	1.3	6
254	Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e299-e305.	0.9	6
255	Assessing the clinical performance of artificial intelligence software for prostate cancer detection on MRI. <i>European Radiology</i> , 2022, 32, 2221-2223.	2.3	6
256	Unresectable Hepatocellular Carcinoma: Serial Early Vascular and Cellular Changes after Transarterial Chemoembolization. <i>Radiology</i> , 2009, 250, 324-326.	3.6	5
257	Magnetic Resonance Imaging, Digital Mammography, and Sonography: Tumor Characteristics and Tumor Biology in Primary Setting. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 15-20.	0.9	5
258	Phase I Study of Nintedanib Incorporating Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Advanced Solid Tumors. <i>Oncologist</i> , 2015, 20, 368-369.	1.9	5
259	Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer. <i>Targeted Oncology</i> , 2017, 12, 229-234.	1.7	5
260	Adding Colour to the Grey Zone of Advanced Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 123-124.	1.6	5
261	Radiologists Should Integrate Clinical Risk Factors with MRI Findings for Meaningful Prostate Cancer Staging. <i>Radiology</i> , 2020, 296, 96-97.	3.6	5
262	The value of immediate cytological evaluation for needle aspiration lung biopsy. <i>Clinical Radiology</i> , 1995, 50, 350-351.	0.5	4
263	Phrenic artery injury—a rare complication of percutaneous needle lung biopsy. <i>British Journal of Radiology</i> , 1996, 69, 356-358.	1.0	4
264	USPIO ? enhanced rectal cancer specimen MRI: how well does it correlate with node identification at histopathology?. <i>Colorectal Disease</i> , 2006, 8, 721-721.	0.7	4
265	Magnetic Resonance Imaging for Tailoring the Need to Biopsy During Follow-up for Men on Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2021, 80, 564-566.	0.9	4
266	Patterns of disease progression in patients with local and metastatic breast cancer as evaluated by whole-body magnetic resonance imaging. <i>Breast</i> , 2018, 40, 82-84.	0.9	3
267	Application of diffusion-weighted whole-body MRI for response monitoring in multiple myeloma after chemotherapy: a systematic review and meta-analysis. <i>European Radiology</i> , 2022, 32, 2135-2148.	2.3	3
268	Balancing the benefits and harms of MRI-directed biopsy pathways. <i>European Radiology</i> , 2022, 32, 2326-2329.	2.3	3
269	Diffusion-weighted MRI of female pelvic tumors. , 2010, , 119-143.		2
270	Eye and testicular pain after administration of gadopentetate dimeglumine.. <i>American Journal of Roentgenology</i> , 1995, 165, 484-485.	1.0	2

#	ARTICLE	IF	CITATIONS
271	Recent advances in oncological imaging. <i>Clinical Medicine</i> , 2003, 3, 318-322.	0.8	2
272	Dynamic Contrast-Enhanced MRI of Prostate Cancer. , 2005, , 191-213.		2
273	Dynamic Magnetic Resonance Imaging in Breast Cancer. , 2005, , 145-173.		2
274	Simulation of Microcirculation in Solid Tumors. , 2007, , .		2
275	Whole-body MRI and diffusion MRI. <i>Cancer Imaging</i> , 2014, 14, .	1.2	2
276	Will Magnetic Resonance Imaging-guided Biopsy Replace Systematic Biopsy?. <i>European Urology Focus</i> , 2015, 1, 152-155.	1.6	2
277	Radium-223: Disease response and fracture assessment by whole body diffusion-weighted MRI (WB-DWMRI) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5024-5024.	0.8	2
278	Population-based prostate cancer screening using a prospective, blinded, paired screen-positive comparison of PSA and fast MRI: The IP1-PROSTAGRAM study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5513-5513.	0.8	2
279	Fast Magnetic Resonance Imaging as a Viable Method for Directing the Prostate Cancer Diagnostic Pathway. <i>European Urology Oncology</i> , 2021, 4, 863-865.	2.6	1
280	Can Diagnostic Magnetic Resonance Imaging for Suspected Clinically Significant Prostate Cancer Predict Unfavorable Long-term Outcome for Diagnosed Men for Pretreatment Counseling?. <i>European Urology Oncology</i> , 2021, 4, 529-531.	2.6	1
281	ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologistsâ€™ training. , 2020, 30, 5404.		1
282	Re: Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling. <i>European Urology</i> , 2022, , .	0.9	1
283	Audit of cancer yields after prostate MRI using both the PI-RADS version 2 and Likert scoring systems. <i>Clinical Radiology</i> , 2022, 77, 541-547.	0.5	1
284	Numerical Study of Tumour Blood Perfusion Based on 3D Tumour Angiogenic Microvasculatures. , 2008, , .		0
285	New Therapies and Functional-Molecular Imaging. , 2014, , 77-96.		0
286	One-Step Systemic Staging for Patients with Breast Cancer. , 2017, , 265-276.		0
287	Simulation of Blood Perfusion in Tumour Microvasculature. , 2007, , .		0
288	Diffusion-Weighted Imaging. , 2009, , 685-706.		0

#	ARTICLE	IF	CITATIONS
289	MRI to Assess Vascular Disruptive Agents. , 2010, , 137-163.		0
290	Beware the stronger magnet.. American Journal of Roentgenology, 1999, 173, 243-243.	1.0	0